A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ALS-008176 in Healthy Japanese Adult Participants
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-06-23
- Last Posted Date
- 2016-07-11
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 24
- Registration Number
- NCT02478333
A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-04-01
- Last Posted Date
- 2018-12-21
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 51
- Registration Number
- NCT02405858
An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2019-11-01
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 6
- Registration Number
- NCT02365623
Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer Dementia
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-02-10
- Last Posted Date
- 2019-02-04
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 18
- Registration Number
- NCT02360657
An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
- First Posted Date
- 2015-01-22
- Last Posted Date
- 2019-10-24
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 21
- Registration Number
- NCT02343744
An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-12-24
- Last Posted Date
- 2020-05-22
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 192
- Registration Number
- NCT02325219
Safety, Pharmacokinetics, and Pharmacodynamics Study of Single Dose of CNTO 3649 in Healthy Adult Men and Multiple Doses of CNTO 3649 in Participants With Type 2 Diabetes Mellitus
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-08-25
- Last Posted Date
- 2014-09-09
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 64
- Registration Number
- NCT02224118
A Safety, Tolerability and Pharmacokinetics Study of JNJ-54861911 in Healthy Japanese Male Participants
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-07-02
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 24
- Registration Number
- NCT02180269
Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma
- First Posted Date
- 2014-06-23
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 16
- Registration Number
- NCT02169180
A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2014-06-13
- Last Posted Date
- 2020-04-27
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 6
- Registration Number
- NCT02162836
© Copyright 2024. All Rights Reserved by MedPath